ARTICLE | Clinical News
Dificid: Phase IIIb started
November 5, 2012 8:00 AM UTC
Optimer began the double-blind, placebo-controlled, U.S. Phase IIIb DEFLECT-1 trial to evaluate 200 mg oral Dificid once daily in about 340 patients undergoing hematopoietic stem cell transplant (HSCT). Dificid is approved to treat CDAD in the U.S. and the EU, where it is known as Dificlir. ...